For identification of actionable and prognostic hotspot mutations in solid tumors. Detects frequent cancer hotspot mutations (SNVs) in tumor samples.
The Tumor Hotspot MASTR™ Plus is a molecular assay (research use only) for the identification of SNVs and CNAs in frequently mutated genes in solid tumors. The assay is designed in collaboration with the ‘Institut National du Cancer’ (INCa) of France using their clinically relevant selection of frequently occurring mutations (hotspots) in 26 genes. The panel focuses on actionable hotspot mutations in a wide variety of solid tumors. This means they have either therapeutic or prognostic value for different solid tumors, enabling a personalized medicine approach.
Multiplicom’s Tumor Hotspot MASTR Plus assay is provided as a ready-to-use kit that offers robust performance with minimum hands-on time. All reagents necessary to enable multiplex amplification of 252 amplicons (121-254 bp) in 4 PCR reactions are included. The assay builds on Multiplicom’s expertise of multiplex assays, and is further optimized to detect mutations using DNA derived from FFPE tumor samples, but is also compatible with FFT samples or detection of mutations in germline DNA.
The assay is compatible with current Massively Parallel Sequencing (MPS) systems, providing the flexibility to choose your preferred method.